EU fördert Mitarbeiterweiterbildung

14 December 2022 Auch im Jahr 2022 wurde die Weiterentwicklung der VEROVACCiNES GmbH vorangetrieben. Mit Hilfe einer Förderung der beruflichen Weiterbildung von Beschäftigten in Unternehmen aus Mitteln des Europäischen Sozialfonds (ESF) konnten mehrere Mitarbeiter in den Bereichen „Good Manufacturing Practice“ und „Good Laboratory Practice“ weitergebildet werden. Mit diesen Maßnahmen wird das Qualitätsniveau weiter gehoben.

Verovaccines paves way for manufacturing its vaccines

12 October 2022 Verovaccines upscales manufacturing processes of its yeast-based vaccines to industrial scale This is an important milestone on the road to commercialization of this novel vaccine class Read more

Animal AgTech Innovation Summit 2022, Amsterdam

12 October 2022 We will be attending the summit also this year. We are excited to discuss new innovations, collaborations and partnerships with you. Come and reach out to us.

11. – 14.10.2022 World Vaccine Congress in Barcelona

11 October 2022 World Vaccine Congress in Barcelona Dr. Hanjo Hennemann will present Verovaccines subunit vaccine platform in the workshop „Platform Technologies“. The workshop will highlight different vaccine technologies (BioNTech, Curevac, ZAPI, CEPI, Verovaccines) and feedback from the regulatory perspective (EMA-TBC, Paul-Ehrlich-Institute). Meet us at the conference!

07. – 09.07.2022 11. Leipziger Tierärztekongress

07 September 2022 11th Leipzig Veterinary Congress 2022 We will be attending this year’s Leipzig Veterinary Congress. We are looking forward to an update on the needs in the animal health field, extending the professional network and learning about new applications of our vaccine technology.

VEROVACCiNES is now using a twin fermenter – many thanks to INFORS HT

24 March 2022 The new twin-fermenter will enable us to boost the number of fermentation runs in order to speed up optimization of manufacturing (upstream processing) generate quality data for our K. lactis yeast system (run-to-run consistency: biomass yield, antigen content, process reliability…) produce vaccine material for efficacy and safety trials under highly controlled conditions https://www.verovaccines.com/wp-content/uploads/2022/08/Timelapse-Fermenter-HD-1min-fin.mp4

VEROVACCiNES establishes Advisory Board and fills key position

17 February 2022 Verovaccines establishes advisory board with internationally experienced members from the vaccine world Ulrike Diesterbeck, DVM takes over the position of Head of Development The aim is to accelerate in-house vaccine development and bring new animal vaccines to market faster Read more

2022, Feb 22. – 23.: Animal Health Innovation Europe

22 January 2022 A planned face-to-face conference will take place in London on 22-23 February 2022. We look forward to meeting our business partners in person again.

VEROVACCiNES closes Series B financing with consortium of investors from Germany and Switzerland

14 October 2021 Vaccine specialist closes Mid-Seven-Figure Series B Financing Round Shareholder group expanded by four new investors with important expertise The fresh funding will be used to drive several vaccine programs into regulatory development Read more

2021, Oct 19. – 20.: Animal AgTech Innovation Summit

19 September 2021 The Animal AgTech Innovation Summit will take place for the third time on 19 and 20 October and we were there from the very beginning. Of course, we won’t miss it this time either. We look forward to seeing you there – even if digitally again.